GlobeNewswire by notified

Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio

Share
  • Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1
  • Ocular hypertension affects over 5% of all adults2; the eye does not properly drain fluid, causing eye pressure to build up3

  • Sandoz manufactures high-impact medicines that bring savings to US patients and support the sustainability of the overall US healthcare system

Basel, April 14, 2022 — Sandoz, a global leader in generic and biosimilar medicines, today announced the US launch of its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, an AB-rated generic equivalent to AbbVie’s COMBIGAN®*, to lower eye pressure in patients with ocular hypertension (high eye pressure).1 This prescription eyedrop is immediately available to patients via retail pharmacies.

Anyone can develop ocular hypertension, but certain groups are at higher risk, including but not limited to African Americans and Hispanics, people over age 40, people living with diabetes or high blood pressure, people who are very myopic (near-sighted) and people who take long-term steroid medicines.4 It is important to treat high eye pressure before it causes damage to the optic nerve and vision loss.5

“Fixed combinations of medicines to treat ocular hypertension can offer patients enhanced convenience, improved adherence, reduced exposure to preservatives, and cost savings,” said Keren Haruvi, President, Sandoz Inc. “We developed this important generic eye treatment in-house to expand patient access to high-quality, more affordable eye care for millions of US patients.”

Sandoz is a leading provider of ophthalmic medicines in the US, with over 36 product families for the treatment of a wide range of eye diseases. The launch of generic brimonidine tartrate/timolol maleate combination eyedrops in the US expands the Sandoz ophthalmology portfolio, helping maintain its #1 position in the US generic ophthalmic space.6

* COMBIGAN® and its design are registered trademarks of Allergan, Inc., an AbbVie company.

Important Safety Information

Contraindications

  • Bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease.
  • Sinus bradycardia, atrioventricular block, overt cardiac failure, cardiogenic shock.
  • Neonates and infants (under the age of 2 years).
  • Hypersensitivity to any component of this product.

Warnings and Precautions

  • Potential for Severe Respiratory or Cardiac Reactions
  • Cardiac Failure
  • Obstructive Pulmonary Disease
  • Potentiation of Vascular Insufficiency
  • Increased Reactivity to Allergens
  • Potentiation of Muscle Weakness
  • Masking of Hypoglycemic Symptoms in Patients with Diabetes
  • Mellitus
  • Masking of Thyrotoxicosis
  • Ocular Hypersensitivity

Adverse Reactions

Most common adverse reactions occurring in approximately 5 to 15% of patients included allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning, and stinging.

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions

  • Antihypertensives/cardiac glycosides may lower blood pressure.
  • Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade.
  • Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension.
  • Catecholamine-depleting drugs may have additive effects and produce hypotension and/or marked bradycardia.
  • Use with CNS depressants may result in an additive or potentiating effect.
  • Digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.
  • CYP2D6 inhibitors may potentiate systemic beta-blockade.
  • Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine.
  • Monoamine oxidase inhibitors may result in increased hypotension.

Use in Specific Populations

Not for use in children below the age of 2 years. Use with caution in children ≥2 years of age.

Please see Full Prescribing Information for additional safety information.

Indication and Usage

Brimonidine tartrate and timolol maleate ophthalmic solution, 0.2%/0.5% is an alpha-adrenergic receptor agonist with a betaadrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP; the IOP-lowering of brimonidine tartrate and timolol maleate ophthalmic solution, 0.2%/0.5% dosed twice a day was slightly less than that seen with the concomitant administration of timolol maleate ophthalmic solution, 0.5% dosed twice a day and brimonidine tartrate ophthalmic solution, 0.2% dosed three times per day.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2021 sales of USD 9.6 billion.

Sandoz on social media:
LinkedIn: https://www.linkedin.com/company/sandoz
Twitter: https://twitter.com/sandoz_global
Facebook: https://www.facebook.com/sandozglobal/
Instagram: https://www.instagram.com/sandozglobal

CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/

References

  1. Brimonidine tartrate/timolol maleate solution/drops. Prescribing information. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af21d2e5-0029-4889-ba93-6417baa91ce6. Accessed on April 12, 2022.
  2. Lazarus R. Ocular Hypertension. Optometrists Network. https://www.optometrists.org/general-practice-optometry/guide-to-eye-conditions/glaucoma-guide/glaucoma/ocular-hypertension/. Published July 4, 2021. Accessed on January 20, 2022.
  3. Boyd K. What Is Ocular Hypertension? American Academy of Ophthalmology. https://www.aao.org/eye-health/diseases/what-is-ocular-hypertension. Published March 9, 2021. Accessed January 21, 2022.
  4. Boyd K. Ocular Hypertension Causes. American Academy of Ophthalmology. https://www.aao.org/eye-health/diseases/ocular-hypertension-cause. Published March 9, 2021. Accessed January 21, 2022.
  5. Boyd K. Ocular Hypertension Diagnosis and Treatment. American Academy of Ophthalmology. https://www.aao.org/eye-health/diseases/ocular-hypertension-treatment. Published March 9, 2021. Accessed January 21, 2022.
  6. Generic Prescription Ophthalmology Market in Sales and Volume Measures. IQVIA MAT. Ending November 2021. Accessed on January 19, 2022.

# # #

Sandoz Global Communications

Chris Lewis
Sandoz Global Communications
+49 174 244 9501 (mobile)
chris.lewis@sandoz.com

Michelle Bauman
Sandoz Global Communications
+1 973 714 8043 (mobile)
michelle.bauman@sandoz.com

Novartis Media Relations
E-mail: media.relations@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

CentralNorth America
Samir Shah+41 61 324 7944Sloan Simpson+1 862 778 5052
Nicole Zinsli-Somm        
Isabella Zinck
+41 79 325 2084
+41 61 324 7188
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ERYTECH to Present at the H.C. Wainwright Global Investment Conference17.5.2022 22:05:00 CEST | Press release

ERYTECHtoPresent at the H.C. WainwrightGlobal Investment Conference Cambridge, MA (U.S.) and Lyon (France), May 17, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its Chief Executive Officer, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference. The conference will be held in a hybrid format from May 23-26, 2022, in Miami, USA. The corporate presentation will be held in person on Wednesday, May 25 at 10:30am ET and will be available on-line on the conference website afterwards. Mr. Beyen will be available for one-to-one meetings with investors on May 24, 25 and 26. If you would like to arrange a one-on-one meeting or register, please contact your conference representative. For more information on the H.C. Wainwright 23rd Global Investment Conference, please visit the H.C. Wainwright Conference websi

EVS COMMUNICATES THE RESULTS OF THE ORDINARY GENERAL MEETING17.5.2022 21:59:34 CEST | Press release

Publication on May17, 2022, after market closure Regulated information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVSCOMMUNICATES THERESULTSOFTHEORDINARYGENERAL MEETING EVS Broadcast Equipment SA, leading provider of live video production systems, held its Ordinary General Meeting on May 17, 2022. In total 73 shareholders representing 2,799,870 shares, or 19.5% of the company shares, attended by proxy the Ordinary General Meeting held physically at the company's registered office but for which the company had recommended its shareholders to attend by videoconference given the still sensitive health situation. All the resolutions have been approved, i.e.: - The remuneration report, the updated remuneration policy, the discharge of the Directors and the Auditor; - The 2021 annual accounts and the allocation of profits, including a total gross dividend of EUR 1.50 for fiscal year 2021 (such dividend is made up, on the one hand, of the i

SeaLegacy Celebrates the Inaugural Year of The Good Ocean17.5.2022 21:49:59 CEST | Press release

A unified, passionate group of businesses investing in SeaLegacy’s mission to protect the world’s oceans British Columbia, Canada, May 17, 2022 (GLOBE NEWSWIRE) -- When eight companies mostly unknown to one another came together for the first time in May of 2021, they were bound only by a commitment to protect our oceans and planet. Today, these founding members of The Good Ocean are actively supporting SeaLegacy’s commitment to ocean protection. "One of the questions I get asked the most is, 'What can I do?'" says SeaLegacy Co-Founder and President Cristina Mittermeier. "This question comes from individuals, and it also comes from businesses. Increasingly, consumers are demanding the products and services they support with their purchasing power be aligned with their desire to be accountable for their impact on earth. Members of The Good Ocean are addressing that demand and stepping into the crucial role businesses play in conservation work. Together, we are taking steps towards syste

Karolinska Development’s portfolio company Aprea Therapeutics acquires Atrin Pharmaceuticals17.5.2022 16:55:38 CEST | Press release

STOCKHOLM, SWEDEN, May 17 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has completed the acquisition of the privately-held US-based biotechnology company Atrin Pharmaceuticals Inc. Aprea Therapeutics will now prioritize the development of Atrin Pharmaceuticals’ drug candidates, which are being developed to fight cancer by affecting the proteins involved in the ability of tumors to repair damage to their DNA. With the acquisition of Atrin Pharmaceuticals’ portfolio of candidate drugs, Aprea Therapeutics intends to shift its primary focus to the development of ATRN-119, a drug candidate that inhibits an important signaling pathway in DNA damage repair. ATRN-119 will soon be evaluated in clinical phase 1/2a studies in the treatment of malignant solid tumors, both as monotherapy and in combination with standard treatment. In parallel with the development of ATRN-119, separate programs are run with a second-generation ATR i

Karolinska Developments portföljbolag Aprea Therapeutics förvärvar Atrin Pharmaceuticals17.5.2022 16:55:38 CEST | Pressemelding

STOCKHOLM, SVERIGE 17 maj 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics har förvärvat det privatägda amerikanska bioteknikbolaget Atrin Pharmaceuticals Inc. Aprea Therapeutics kommer nu att prioritera utvecklingen av Atrin Pharmaceuticals läkemedelskandidater, vilka utvecklas för att bekämpa cancersjukdomar genom att påverka de proteiner som är involverade i tumörers förmåga att reparera skador i sitt DNA. Efter förvärvet av Atrin Pharmaceuticals läkemedelsprojekt flyttar Aprea Therapeutics sitt primära fokus till utvecklingen av ATRN-119, en läkemedelskandidat som hämmar en viktig signaleringsväg vid reparation av DNA-skador. ATRN-119 kommer inom kort att börja studeras i kliniska fas 1/2a-studier vid behandling av maligna solida tumörer, både som monoterapi och i kombination med standardbehandling. Parallellt med utvecklingen av ATRN-119 bedrivs separata program med en andra generationens ATR-hämmare, ATRN-354, med poten